California, USA-based Affymetrix has fallen into loss in the second quarter of 2008 on a drop in revenue and acquisition charges.
The firm posted a net loss of $3.6 million, or $0.05 per share, versus net income of $1.2 million, or $0.02 per share, in the same period of 2007. Operating expenses were down 8.6% to $50.1 million, which included a restructuring charge of $0.9 million. This was half the cost of restructuring in the year-before period when the firm paid out $1.8 million.
Revenue was down only slightly, 1.6% to $86.9 million. This comprised: product sales of $75.0 million, up 9.6%, including array and reagent sales of $68.9 million and instrument turnover of $6.1 million; service revenue down 25% to 9.0 million; and royalties and other income down 73.3% to $2.9 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze